Argenx SE Completes Acquisition of Forte Biosciences for $77.00 Per Share

Transaction Summary: Argenx SE ($ARGX) has finalized its acquisition of Forte Biosciences, Inc. ($FBRX) via a tender offer, as reported in this final amendment (SC TO-T/A) to the tender offer statement.

Key Details:

• Transaction Type: Completion of Tender Offer and subsequent Merger.
• Offer Price: $77.00 per share in cash.
• Tendered Shares: 19,894,879 shares of Forte common stock were validly tendered before the offer expired on August 26, 2026.
• Total Tender Value: Approximately $1.53 billion.

Outcome: Following the successful tender offer, Argenx's ownership reached approximately 87.13%, satisfying the condition for a short-form merger. Argenx then completed the merger, making Forte Biosciences a wholly-owned subsidiary. Consequently, Forte's common stock ($FBRX) will be delisted from the Nasdaq Capital Market.

Strategic Rationale: The acquisition adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, to Argenx's immunology pipeline.